stockrowRhythm Pharmaceuticals, Inc.
RYTM Healthcare Biotechnology
Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024.
- Revenue
- +79.6%
- EPS
- +26.9%
- Free cash flow
- +95.4%
Quarter to September 2026, against a year earlier
Follow RYTM
Alert me
Rhythm Pharmaceuticals, Inc. (RYTM) Free cash flow
Rhythm Pharmaceuticals, Inc.'s free cash flow for fiscal 2025 was −$156.6M, compared with −$154.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$81.8M. Over the past ten years it has ranged from −$177.7M (fiscal 2022) to −$7.0M (fiscal 2015); the current reading is higher than 18% of that period. Rhythm Pharmaceuticals, Inc. ranks 419th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$156.6M | — |
| FY2024 | −$154.4M | — |
| FY2023 | −$141.9M | — |
| FY2022 | −$177.7M | — |
| FY2021 | −$144.4M | — |
| FY2020 | −$122.2M | — |
| FY2019 | −$126.1M | — |
| FY2018 | −$62.8M | — |
| FY2017 | −$29.6M | — |
| FY2016 | −$24.3M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | −$3.1M | — |
| Jun 2026 | −$9.2M | — |
| Mar 2026 | −$44.2M | — |
| Dec 2025 | −$26.3M | — |
| 38 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| CORT Corcept Therapeutics Incorporated compare | $194.6M |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −$75.1M |
| RYTM Rhythm Pharmaceuticals, Inc. | −$81.8M |
| AXSM Axsome Therapeutics, Inc. compare | −$82.6M |
| ORKA Oruka Therapeutics, Inc. compare | −$101.2M |
| ABVX Abivax SA Sponsored ADR compare | −$226.1M |
| PRAX Praxis Precision Medicines, Inc. compare | −$306.2M |
| IONS Ionis Pharmaceuticals, Inc. compare | −$567.5M |
| CYTK Cytokinetics, Incorporated compare | −$588.6M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on RYTM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement